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Abstract
SV40 has been linked to some human malignancies, and the evidence that this virus plays a causative role in mesothelioma and brain
tumors is mounting. The major SV40 oncoprotein is the Large tumor antigen (Tag). A key Tag transforming activity is connected to its
capability to bind and inactivate cellular p53. In this study we developed an effective, high throughput, ELISA-based method to study
Tag-p53 interaction in vitro. This assay allowed us to screen a chemical library and to identify a chemical inhibitor of the Tag binding to
p53. We propose that our in vitro assay is a useful method to identify molecules that may be used as therapeutic agents for the treatment
of SV40-related human cancers.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
During the last decade a large number of studies have
linked the small DNA oncogenic Simian Virus 40 (SV40) to
some human malignancies (reviewed in Jasani et al., 2001).
These evidences have led three independent panels of sci-
entists to conclusively link SV40 to specific human cancers
(Klein et al., 2002; Wong et al., 2002; I.O.M., 2002). Re-
cently, the Institute of Medicine of the National Academy of
Science has concluded that SV40 can cause human cancer
under natural conditions, and this panel of scientists urged
more research on SV40-related cancers (I.O.M., 2002). Hu-
man malignant mesothelioma (MM) is the human cancer in
which SV40 activities have been studied in more detail.
MM is a tumor of the lining of the lungs, heart, and abdo-
men arising from the malignant transformation of human
mesothelial cells (HM). Chemotherapy is presently ineffec-
tive for mesothelioma patients, who survive on average only
9 months after diagnosis (Carbone et al., 2002).
The overall consensus is that about 50% of MM in the
U.S. contain SV40. The association is highly specific, since
SV40 is present only in MM cells and not in the surrounding
tissues (Carbone et al., 1994; Shivapurkar et al., 1999).
SV40 is biologically active in MM, because the SV40 major
oncoprotein binds its cellular targets in MM specimens
(Carbone et al., 1997; De Luca et al., 1997). SV40 expres-
sion is required for growth of SV40 containing MM; tar-
geting the SV40 major oncoprotein through antisense tech-
nology causes growth arrest and apoptosis in SV40-positive
MM cell lines (Waheed et al., 1999). Furthermore, HM are
uniquely susceptible to SV40-mediated cell transformation
and immortalization (Bocchetta et al., 2000). All these ev-
idences support a causative role of SV40 in MM. The
specific presence of SV40 in tumor cells and not in nearby
stromal cells (Carbone et al., 1994; Shivapurkar et al., 1999)
and the apparent requirement of SV40 Tag expression for
tumor growth (Waheed et al., 1999; Cacciotti et al., 2001)
suggest a possible benefit of novel therapies targeting
SV40-positive cells expressing Tag.
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SV40 is a small DNA virus that drives the host cell into
S-phase through the concerted actions of the two SV40-
encoded oncoproteins: the large tumor antigen (or Tag), and
the small tumor antigen (or tag). The SV40 Tag is the major
SV40 oncogenic protein. It is a highly multifunctional pro-
tein targeting a number of host’s proteins, all involved in
cell-cycle control, chromosomal stability, and protein fold-
ing (reviewed in Ali and DeCaprio, 2001). A key Tag
function in the process of SV40-dependent cell transforma-
tion is represented by Tag binding to (and consequent in-
activation of) cellular p53. In fact, the latter is considered
one of the most critical G1/S transition checkpoint and
apoptosis regulators (Levine, 1997). Given the critical im-
portance of the Tag–p53 interaction in the process of SV40-
driven oncogenesis, we inferred that the identification of a
group of chemicals abolishing such interaction would rep-
resent a valuable source for the future development of
SV40-specific anticancer drugs.
Results and discussion
We have previously shown that human mesothelial cells
are uniquely susceptible to SV40-mediated cell transforma-
tion and immortalization (Bocchetta et al., 2000). A few
weeks after SV40 infection, three-dimensional foci of trans-
formed HM arise; the latter can be cultured and give rise to
immortal cell lines. SV40-transformed HM are a valuable
source of Tag for molecular pharmacology studies because
in these cells Tag directly sustains the transformed pheno-
type, and therefore, Tag is anticipated to possess in these
cells all the posttranslational modifications required for its
oncogenic functions. Furthermore, SV40-transformed HM
contain exceptionally high amounts of Tag (about 1% of the
whole crude cell extract) bound to p53 (Fig. 1). These two
features render SV40-transformed HM lines unique sources
of Tag–p53 complexes for pharmaceutical biotechnology
purposes. For this reason we planned to develop an in vitro
system for high throughput analysis of the Tag–p53 inter-
action that allowed us to screen a chemical library to iden-
tify compounds inhibiting Tag binding to p53.
We first attempted to construct a recombinant SV40
virus encoding a modified Tag with a 16-amino-acid linker
and six histidines at its C-terminal portion. This was done to
create a Tag that could have been complexed to insoluble
carriers and purified by means of nickel-conjugated carriers
(Janknecht et al., 1991). The resulting recombinant virus
(named SV40CT) replicated into African green monkey kid-
Fig. 1. (A) Levels of Tag and p53 expression in SV40-transformed HM line. Lanes: 1, 100 g of total protein lysate obtained from SV40CT-transformed HM;
2, 100 g of total protein lysate obtained from SV40-transformed HM cells F1; 3 through 7, purified Tag (MBR) (lane 3, 0.06 g; lane 4, 0.12 g; lane 5,
0.25 g; lane 6, 0.5 g; lane 7, 1 g). Lanes 8 and 9: two sequential immunoprecipitations of 500 g of F1 total protein lysate using 1 g of Tag-specific
antibody (lane 7), and then 4 g of the same antibody (lane 8). Immunoprecipitates were run on a 10% SDS–PAGE and transferred to a nitrocellulose
membrane. The top half of the membrane was hybridized with Tag-specific antibody, while the bottom half was hybridized for p53. Antibodies used are
specified under Materials and methods. Please note that bands in lanes 8 and 9 are not quantitatively comparable to those in lanes 1 through 7. These
experiments show that large amounts of p53 can be coimmunoprecipitated along with Tag from F1 cell lysates. We have attempted to quantify the percentage
of p53 not bound to Tag. We obtained variable results using different techniques (p53 is known to bind nonspecifically to different carriers). Despite this
quantitative variability, it appears that a fraction of p53 is not bound to Tag in F1 cells (not shown). Please note that in these conditions, the Western blot
hybridization becomes linear for amounts of Tag higher than 0.12 g (compare lanes 3 and 4 to lanes 5 through 6). (B) Coomassie blue staining of 1 g
of the purified Tag preparation (MBR) used in (A). Molecular weight markers are reported in the figure.
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ney cells, infected, and transformed primary HM similarly
to wild-type SV40 (not shown). SV40CT-transformed HM
expressed amounts of recombinant Tag (TagCT) similar to
those of wild-type SV40-transformed HM (Fig. 1, lanes 1
and 2). Altogether, these observations indicated that a 22-
amino-acid insertion at the Tag C-terminus does not inter-
fere with most of the functions of this oncoprotein and with
SV40 replication in both monkey and human hosts. Previ-
ous observations have pointed out that the Tag carboxy-
terminal plays a minor role in SV40 DNA replication and in
Tag-mediated transformations (Fanning and Knippers,
1992). Rather, this domain appears to be implicated in
facilitating SV40 capsid proteins expression. However, this
function is maintained even when the C-terminal domain is
physically separated from Tag (Tornow et al., 1985), and
major phenotypical changes where observed mainly when
the sequence of the C-terminal domain of Tag was grossly
mutated through frameshifting (Schneider et al., 1988). So,
the preservation of the C-terminal domain yielded a func-
tional recombinant SV40 virus despite a 22-amino-acid in-
sertion at the very C-terminus of Tag. However, TagCT
failed to reproducibly bind to Ni-conjugated carriers, sug-
gesting that the TagCT C-terminal portion is not readily
accessible to Ni-conjugated carriers.
We then resorted to a more traditional ELISA-based
approach, which is a modification of a previously published
technique (Gannon and Lane, 1987), and the principle of
that is outlined in Fig. 2A. According to this method a
biotinylated antibody-specific for Tag was bound to strepta-
vidin-conjugated 96-well plates. Subsequently, Tag–p53
complexes were sequestered from total cell lysates by the
anti-Tag antibody and identified by using a second antibody
specific for p53. Since the latter antibody was directly con-
jugated to horseradish peroxidase (HRP), the results were
directly visualized by enhanced chemiluminescence (ECL).
Overall, the assay proved to be semiquantitative (Fig. 2B),
and therefore, it would have allowed us to detect both those
chemicals abolishing Tag–p53 interaction and those reduc-
ing the affinity of the binding between these two molecules.
Accordingly, we used the ELISA-based assay to screen the
diversity set library of the NCI Chemotherapeutic Agents
Repository, consisting of about 2  103 compounds. All
molecules causing a reduced ECL signal during the screen-
ing were tested twice, and chemicals that provided repro-
ducible results were analyzed in coimmunoprecipitation/
Western blot assays. The ELISA screening evidenced 11
putative inhibitors of the Tag–p53 binding, but only one
(named B11; its chemical structure is reported in Fig. 3)
specifically inhibited coimmunoprecipitation of p53 along
with Tag (Fig. 3, lane 4). Releasing p53 to its binding to Tag
may potentially cause p53- dependent apoptosis in SV40-
transformed cells. To test this hypothesis, we treated SV40-
transformed HM with the compound B11 at different con-
centrations. However, B11 did not cause death and apopto-
sis in treated cells. Western blot analysis revealed that
treatment of SV40-transformed HM with B11 did not mod-
ify the expression levels of neither p53 nor Tag within 2 h
from treatment (Fig. 4). p53 expression levels decreased 4 h
after the addition of B11. The latter phenomenon may re-
flect the loss of p53 stabilization due to impaired binding to
Tag (a consequence of Tag binding to p53 is the stabiliza-
tion of p53 and therefore Tag binding to p53 increases the
p53 expression levels). Furthermore, the expression levels
of both the proapoptotic protein Bax and the cyclin-depen-
Fig. 3. Compound B11 specifically inhibits Tag-p53 binding. Coimmuno-
precipitation of p53 along with Tag in the presence of different chemicals.
Lanes: 1, 100 g of F1 cells lysate immunoprecipitated in the presence of
33 M of a compound that tested consistently negative in the ELISA-based
assay; 2, negative control; 3, as in lane 1 but using 33 M compound A11;
4, as in lane 1 but using 33 M compound B11; 5, as in lane 1 but using
33 M compound C5. Lanes - empty lanes. Compounds A11, B11, and C5
consistently tested positive in the ELISA assay. However, A11 and C5
inhibited the interaction of Ab-1 antibody with Tag, while B11 only
interfered with Tag-p53 binding. Other compounds that tested positive in
the ELISA assay did not interfere with tag–p53 interactions in immuno-
precipitation assays (not shown). The chemical structure of compound B11
is reported at the bottom.
Fig. 2. ELISA-based in vitro assay for the study of Tag binding to cellular
p53. (A) Schematic summary of the experimental strategy. (B) Autora-
diography of a preliminary assay in which increasing amounts of total cell
lysate were used. Lanes: 1, negative control; 2 through 8, twofold increases
of total protein lysate obtained from F1 cells added in each well (from 2
through 128 g). Note that the assay, in these conditions, appears semi-
quantitative using more than 8 g of total protein lysate (compare lanes 2
through 4 and lanes 5 through 8).
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dent kinase inhibitor p21WAF1/Cip1 decreased after B11
treatment and became barely detectable (or undetectable)
4 h after B11 treatment (Fig. 4A). Since both Bax and
p21WAF1/Cip1 are two downstream effectors transcriptionally
regulated by p53 (Levine, 1997), we inferred that B11 not
only detaches p53 from binding to Tag, but it also inacti-
vates p53, either through locking p53 in a conformationally
inactive state or by interfering with some p53 residues that
are critical for its functions. RNAse A protection experi-
ments supported this interpretation, because the mRNA
expression levels of both Bax and p21WAF1/Cip1 decreased
readily after B11 addition (Fig. 4B). Four hours after B11
treatment p21WAF1/Cip1 mRNA was undetectable by RNAse
A protection assay, while the expression level of the Bax
mRNA decreased about 30 times 4 h after B11 addition
(Fig. 4B, lanes 4).
In conclusion, while B11 is not yet ready to be consid-
ered a potential SV40- specific anticancer drug for clinical
studies, the identification of B11 is important, because B11
could be chemically modified to identify variants of the
molecule that may predominantly target Tag–p53 interac-
tion without inactivating p53. More importantly, the isola-
tion of B11 represents the operative demonstration of the
validity of our ELISA-based approach, which can be used to
screen wider collections of chemicals to identify putative
SV40-specific anticancer drugs. Additionally, B11 is a com-
pound that can be useful for the in vitro study of Tag–p53
association in different systems.
Materials and methods
Cells, lysates, and antibodies
SV40-transformed human mesothelial clone F1 has been
previously described and characterized (Bocchetta et al.,
2000, 2003). F1 cells were grown in T150 flasks; when
confluent, cell layers were dissociated by trypsinization,
harvested, and washed three times in DMEM supplemented
with 5% fetal bovine serum to remove trypsin. Cell pellets
were dissolved in lysis buffer (20 mM Tris–HCl pH 7.4, 150
mM NaCl, 1% NP-40, 0.1% SDS, 1 mM PMSF, and 1
g/ml of each aprotinin, leupeptin, and pepstatin) and kept
in ice for 20 min. Routinely, 0.5–0.8 ml of fresh cell pellet
were dissolved in 5 ml of lysis buffer in a 15 ml falcon tube.
After the incubation in ice, the lysate was spun at 10,000 g
for 5 min, and the resulting supernatant was transferred to a
fresh 15 ml falcon tube, mixed with 5 ml of cold casein in
PBS (Blocker Casein, Pierce) to obtain a “working lysate
solution” and immediately used in the ELISA assay (see
below).
We used the following antibodies: mouse monoclonal
PAb 419 (Ab-1) specific for the N-terminal portion of the
SV40 Tag (1 mg/ml, Oncogene Science), rabbit polyclonal
antibody N-20 specific for Bax (Santa Cruz Biotechnology),
mouse monoclonal antibody Ab 187 specific for p21WAF1/Cip1
(Santa Cruz Biotechnology), mouse monoclonal antibody
MAB374 specific for glyceraldehyde-3-phosphate dehydro-
genase (Chemicon), and mouse monoclonal DO-1 (sc-126
HRP) specific for p53, directly conjugated to HRP (Santa
Cruz Biotechnology). Antibody Ab-1 was biotinylated us-
ing the Biotin-NHS kit following the manufacturer’s proto-
col (Calbiochem). After biotinylation, the antibody was
dialyzed against PBS overnight and stored at 4°C (in these
conditions the antibody was stable for at least 3 weeks).
Purified SV40 Tag was from MBR. Western blot hybrid-
ization was performed as previously described (Bocchetta et
al., 2000, 2003).
In vitro ELISA-based assay for the study of Tag-p53
binding
The assay consisted of trapping Tag–p53 complexes
present in F1 cell lysate in streptavidin-coated 96-well
plates (Reacti-Bind, Pierce) by means of the biotinylated
Ab-1 antibody. After washing out unbound material, a sec-
ondary antibody directly conjugated to HRP and specific for
p53 was added. After a second series of washes, Tag–p53
complexes were evidenced by ECL and read either by using
a luminometer or by autoradiography of the 96-well plate on
an X-ray film. The details were as follows: streptavidin-
coated 96-well plates were blocked over night at 4°C using
150 l/well of casein/PBS blocker. Then, 100 l of 30
g/ml biotinylated Ab-1 in casein/PBS blocker were added
to each well and incubated at 4°C for 1 h. Then unbound
antibody was removed from the 96-well plate by inverting
Fig. 4. B11 treatment of SV40-transformed F1 cells causes down-regula-
tion proteins that are transcriptionally regulated by p53. (A) Western blot
analysis of 50 g of total protein extracts obtained from F1 cells (lane 1),
F1 cells 1 h after exposure to 15 M of B11 (lane 2), F1 cells 2 h after
exposure to 15 M of B11 (lane 3), and F1 cells 4 h after exposure to 15
M of B11 (lane 4). The identity of each band is reported on the right side
of each panel. GAPDH: glyceraldehyde-3-phosphate dehydrogenase. Nar-
rower bands in lanes 4 for p21 and p53 reflect differences in the level of
expression of these two proteins. This result has been confirmed in three
independent experiments. (B) RNAse A protection assay performed on
total RNA extracted from F1 cells and from F1 cells treated with 15 M
of B11 at different time points. Lanes: 1, 1/100 of riboprobe used in each
reaction; 2, no total RNA reaction; 3, F1 0 h; 4, F1 1 h after B11 addition;
5, F1 2 h after B11 addition; 6, F1 4 h after B11 addition.
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the plate and tapping it vigorously on a dry paper towel (this
same technique was used to remove all solutions from the
wells in downstream handling of the streptavidin-coated
plates). Subsequently, 100 l of working lysate solution
(see above) was added to each well and incubated at 4°C for
2 h. For screening of the chemical library (Diversity set,
NCI-Chemotherapeutic Agents Repository), 3 l of each
compound (final concentration of chemicals; 33 M) was
added to each well. Positive controls were represented by
wells where no random chemical was added, while negative
controls were represented by wells receiving nonbiotiny-
lated Ab-1 antibody. After the incubation, plates were
washed three times with PBS, then 100 l of 50 ng/ml
HRP-conjugated DO-1 antibody in casein/PBS blocker was
added in each well and incubated at 4°C for 45 min. At the
end of the latter incubation, wells were washed four times
with PBS, received 100 l of ECL substrate (SuperSignal
West Dura, Pierce), diluted 1:10 in PBS, and analyzed. For
analysis of the results plates were laid on X-ray films (Fuji)
for 20 s in a dark room. Chemicals contained by samples
displaying lack or reduced ECL signal were tested for a
second time, and molecules tested “double-positive” in the
ELISA-based assay were analyzed by coimmunoprecipita-
tion experiments. The latter was performed as previously
described (Bocchetta et al., 2000), with the exception that
test samples contained 33 M final concentration of the
chemical to be analyzed.
RNAse A protection assay
These assays were conducted essentially as described in
Bocchetta et al. (2003). Riboprobes used in the assays were
transcribed from DNA fragments obtained by PCR reac-
tions using a lung cDNA library (ResGen) as the template.
PCR primers were the following: 5-GGATTCGCCGAG-
GCACCGAG-3 and 5-TAATACGACTCACTATAGGG-
CTCGGTGCCTCGGCGAATCC-3 (used for p21 amplifi-
cation); 5-ATCCAGGATCGAGCAGGGCG-3 and 5
TAATACGACTCACTATAGGGCCTTGAGCACCAGT-
TTG-3 (used for Bax amplification); 5ATGGGGAAGGT-
GAAGGTCGG-3 and 5 TAATACGACTCACTATAGG-
GATGCCCTTGAGGGGGCC-3 (used for glyceraldehyde-
3-phosphate dehydrogenase amplification; all reverse
primers had fused in their 5 portion a T7 promoter se-
quence, underlined in the primer sequences). PCR reaction
was gel purified and then T7-transcribed in vitro in the
presence of 50 Ci of [32P]UTP according to standard
protocols. In synthesis, transcription of the p21 fragment
yielded a 453-bases transcript complementary to positions
41–494 of the p21 mRNA (coding sequence); the Bax
template yielded a 282-bases transcript complementary to
positions 91–373 of the Bax mRNA (coding sequence), and
the GAPDH fragment yielded a 820-bases transcript com-
plementary to positions 1–820 of the GAPDH mRNA (cod-
ing sequence). After transcription, reactions were incubated
with RNAse-free DNAse I (MBI Fermentas) for 15 s at
room temperature and purified by gel-filtration using
Chroma spin columns (Clontech). Total RNA was extracted
from cells according to standard methods, and its integrity
was verified on denaturing agarose gels. Then 60 g of total
RNA from each sample was mixed with 1/20 of the radio-
active riboprobe in 25 l (final reaction volume) of anneal-
ing buffer (50 mM Tris–HCl pH 7.4, 100 mM NaCl, 0.1
mg/ml BSA). Annealing reactions were overlaid with min-
eral oil, incubated at 75°C for 15 s, and then incubated at
68°C for 2 h. At the end of the annealing reaction, each
sample received 5 l of 40 g/ml RNAase A (Sigma) in TE
buffer, and then samples were incubated at 37°C for 15 s. At
the end of the incubation, each sample received 30 l of
formamide and was loaded on a 6% sequencing gel. Neg-
ative controls consisted of mock reactions containing no
total RNA. At the end of the run gels were dried and
exposed to both X-ray films and to a phosphoimager FLA-
2000 (Fuji film).
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